Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Our volunteers generously give us their time, skills and experience to tell people about our work, and to help us raise vital funds for research into better treatments and ultimately a cure for T1D.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Type 1 Diabetes Grand Challenge launches first research call
Following the exciting announcement in April about a new partnership between the Steve Morgan Foundation, Diabetes UK and JDRF to invest £50m into game-changing type 1 diabetes research, we have opened our first funding round, calling scientists to submit research proposals that could be transformational for people with type 1 diabetes.
First-class research cannot happen without first class researchers. Diabetes UK and JDRF are committed to nurturing the diabetes research leaders of the future, so for the first research call we have worked together to develop a new senior fellowship programme.
Fellowships are awards for individual researchers that support them to develop their careers, build their own research teams, and make diabetes research their life’s work.
The new Type 1 Diabetes Senior Research Fellowship will allow exceptional researchers, with a track-record of impactful research, to become world leaders in their field and lead the race for new treatments and a cure for type 1 diabetes.
The fellowship will award scientists up to £1.5 million to research:
These areas, along with novel insulins, were identified as carrying the most potential to improve the lives of people with type 1 diabetes and propel us towards a cure.
Rachel Connor, Director of Research Partnerships at JDRF, said:
“We believe in the power of research to one day lift the burden of living with type 1 diabetes, and alongside our partners in the Type 1 Diabetes Grand Challenge we are proud to launch this Senior Fellowship to enable researchers to pursue new ideas to transform lives for people with type 1 diabetes.
We can’t wait to see how this opportunity will deliver in supporting the cutting edge research that the Type 1 Diabetes Grand Challenge has set out to inspire.”
The research community will have until September 2022 to shape their ideas and apply for the fellowship. Diabetes UK and JDRF will then work with research experts and people living with or affected by type 1 diabetes to review the applications. They will select those submitted by researchers with exceptional track-records and that involve the highest quality science, with the greatest chance of benefiting people with type 1 diabetes. We expect to announce the final funding decisions in early 2023 and will keep you updated.
This fellowship will be administered by Diabetes UK on behalf of the Type 1 Diabetes Grand Challenge Partnership.
If you’re a diabetes researcher, find out more information about the call and application process.
New research suggests that B cells play a major role in damaging protective immune cells called Tregs. Protecting Tregs could help protect insulin-producing cells in the early stages of T1D.
A major UK study has shown that screening children for type 1 diabetes (T1D) can identify the condition in its earliest stages, before symptoms appear, offering families time, choices, and hope.
The European Commission has approved Teizeild, the European brand name for the immunotherapy teplizumab, for use in people with stage 2 type 1 diabetes (T1D). This marks an important step forward in efforts to delay the progression of the condition.
Highlights from an extraordinary year in type 1 diabetes (T1D) research, treatment, advocacy and policy.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
